ARS Pharmaceuticals, Inc. (SPRY)
(Delayed Data from NSDQ)
$9.79 USD
-0.14 (-1.41%)
Updated Sep 19, 2025 04:00 PM ET
After-Market: $9.98 +0.19 (1.94%) 7:58 PM ET
4-Sell of 5 4
D Value F Growth A Momentum F VGM
Fundamental Charts
About Price to Cash Flow
The Price to Cash Flow ratio or P/CF is price divided by its cash flow per share. It's another great way to determine whether a company is undervalued or overvalued with the denominator being cash flow. One of the reasons why some investors prefer the P/CF ratio over the P/E ratio is because the net income of the cash flow portion rightly adds depreciation and amortization back in since these are not cash expenditures. In contrast, the net income that goes into the earnings portion of the P/E ratio does not add these in, thus artificially reducing the income and skewing the P/E ratio. Like the P/E ratio, a lower number is considered better. A value under 20 is generally considered good.
SPRY 9.79 -0.14(-1.41%)
Will SPRY be a Portfolio Killer in September?
Zacks Investment Research is releasing its prediction for SPRY based on the 1-3 month trading system that more than doubles the S&P 500.
Zacks News for SPRY
ARS Pharmaceuticals, Inc. (SPRY) Reports Q2 Loss, Beats Revenue Estimates
4D Molecular Therapeutics, Inc. (FDMT) Reports Q2 Loss, Misses Revenue Estimates
SPRY: What are Zacks experts saying now?
Zacks Private Portfolio Services
Corcept Therapeutics (CORT) Tops Q2 Earnings Estimates
Here's What Could Help ARS Pharmaceuticals, Inc. (SPRY) Maintain Its Recent Price Strength
Catalyst Pharmaceutical (CPRX) Reports Next Week: Wall Street Expects Earnings Growth
Other News for SPRY
Is SPRY gaining bearish strength? 1,2,3 Retracement Bearish shows up after slipping 1.41%
Global Expansion and Strategic Advancements Drive Buy Rating for ARS Pharmaceuticals
ARS Pharmaceuticals (SPRY) Gains on Japanese Approval for Neffy Nasal Spray
ARS Pharma rises after Japan nod for neffy nasal spray for allergy
SPRY Gains Approval in Japan for Needle-Free Allergy Treatment